Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab + SBRT for Metastatic Head and Neck Carcinoma
NCT03283605Phase 2Completed
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Jul 2018
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Centre hospitalier de l’Université de Montréal. Started Jul 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03283605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283605.